Ask about this productRelated genes to: GDF3 protein
- Gene:
- GDF3 NIH gene
- Name:
- growth differentiation factor 3
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 12p13.31
- Locus Type:
- gene with protein product
- Date approved:
- 1999-04-23
- Date modifiied:
- 2016-10-05
Related products to: GDF3 protein
Related articles to: GDF3 protein
- Spectral photon counting computed tomography (SPCCT) represents a major advancement in diagnostic imaging, with the potential to significantly enhance image contrast and resolution by leveraging photon-counting detectors. The integration of high atomic number nanoparticles (NPs), such as gadolinium fluoride (GdF), expands the scope of SPCCT by enabling combined high-resolution imaging and therapeutic strategies. This study investigates the interactions between SPCCT irradiation and acquisition parameters and surface-functionalized GdTbFNPs, with the goal of optimizing the x-ray-induced activation and imaging protocols. These optimizations are crucial towardapplication of x-ray induced photodynamic therapy (X-PDT).Nanoparticles, synthesized with and without surface modifications, were evaluated for their biocompatibility () and imaging properties (and). SPCCT enabled K-edge imaging to achieve specific gadolinium NP distribution and quantification.experiments revealed a linear relationship between NP concentration and fluorescence intensity, confirming their potential as contrast agent for both K-edge imaging and fluorescence X-PDT. Optimization of emission activation conditions by varying tube voltage (kVp) and tube current (mA) demonstrated that fluorescence intensity increased proportionally with the tube current-time product (mAs).experiments in mice, following subcutaneous injections of functionalized GdTbF@PEG NPs, showed a clear concentration-dependent increase in fluorescence intensity. K-edge imaging further confirmed the specificity and distribution of the NPs.These findings demonstrate the dual capability of GdTbFNPs to act both as efficient contrast agents for x-ray-based imaging and as luminescent probes under x-ray excitation, highlighting their potential for multimodal imaging and X-PDT. - Source: PubMed
Publication date: 2026/09/21
Akl PiaGautheron ArthurAntonuccio Maria NicoleLabour JoeyHoumeau AngèleLanglois Jean-BaptisteYagil YoadLahoud EliasErhard KlausSi-Mohamed SalimMontcel BrunoChaput FrédéricLerouge FrédéricDouek PhilippeCarret Alison - Chronic inflammation is a hallmark of obesity and its associated metabolic disorders. Adipose tissue macrophages (ATMs) play a crucial role in maintaining tissue homeostasis and orchestrating metabolic inflammation. Importantly, the regulation of proinflammatory gene translation is critical for macrophage activation, a process that has been closely linked to the onset of insulin resistance and type 2 diabetes. Histone deacetylase 3 (HDAC3) is a contributing factor of inflammatory gene expression; however, its precise role in modulating adipose tissue inflammation and type 2 diabetes remains poorly understood. This study demonstrates that metabolically stressed-induced HDAC3 mediates ATMs inflammation. HDAC3 deficiency in macrophages reduces adipose tissue macrophage infiltration and fibrosis, improves hyperglycemia, and reduced weight gain, adiposity in diet-induced obesity mice. HDAC3 deficiency mitigated the chronic inflammation and fibrosis in adipose tissue by suppressing inflammatory cytokine production via H3K4Me3/H3K27Ac-mediated chromatin remodeling. Mechanistically, growth differentiation factor 3 (GDF3) functions as a sensor of metabolic stress, interacts with HDAC3 through histone modification-mediated chromatin remodeling of inflammation genes. Critically, HDAC3 and GDF3 co-expression increased in adipose tissue/ATMs of obese humans, correlating positively with BMI, blood glucose, and proinflammatory gene levels. Our finding identifies HDAC3 as a molecular nexus connecting ATMs activation to systemic insulin resistance and type 2 diabetes. The GDF3-HDAC3 axis drives transcriptional reprogramming through H3K4Me3/H3K27Ac modifications, revealing a novel therapeutic target for obesity-associated metabolic disease. - Source: PubMed
Publication date: 2026/09/12
Zhang YulinChen YeLiu JiaLiu YanZhan RongrongTao XinyiChen HaoranDong HaoLu WenjieLuo QichaoGao ShanKong Qin - Growth differentiation factor 3 (GDF3), a TGFβ superfamily cytokine, has been linked to visceral adipose proliferation and adiposity in animal studies. However, the relationship between circulating GDF3 levels and visceral adiposity in humans remains unclear. This study aimed to assess the potential of serum GDF3 as a biomarker for visceral obesity. - Source: PubMed
Publication date: 2026/08/13
Li ZhaozhiLi JiaoyangOuyang YunJiang LiyanLiao ZhezhenRan LiYang FeiXiao XinhuaWang Yadi - - Source: PubMed
Publication date: 2026/07/18
Xia FangqiHu YaqiWang YaqiXue MengzhenZhu LeiqiLi YuanyangZhang YifanWang ShuwenWang RuiYuan QiHe YuminYuan DingZhang JihongYuan Chengfu - Prostate cancer is a prevalent disease with diverse tumor characteristics that complicate treatment. The integration of spatial patterns from prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT), pathology and expanding genomic data represents a groundbreaking advancement in histo-imaging genomics. The aim of this study was to elucidate the internetwork mapping between genetic biomarkers and PSMA PET/CT imaging in prostate cancer patients. - Source: PubMed
Publication date: 2026/07/04
Qu LiliLi KaiyueWang MuwenXiao YadiJin XinZhou HangYuan LujieLi YuekaiWang ShiweiLi RuiHacker MarcusLi XinLi Xiang